B. Riley started coverage on shares of Inogen (NASDAQ:INGN - Free Report) in a report released on Monday, MarketBeat reports. The brokerage issued a buy rating and a $14.00 price objective on the medical technology company's stock. B. Riley also issued estimates for Inogen's Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($0.95) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.17) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.72) EPS.
Other analysts have also issued reports about the stock. Stifel Nicolaus dropped their price target on shares of Inogen from $10.00 to $7.00 and set a "hold" rating on the stock in a research report on Thursday, May 8th. Wall Street Zen lowered shares of Inogen from a "buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC raised shares of Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 price target on the stock in a research report on Thursday, May 22nd.
Check Out Our Latest Analysis on INGN
Inogen Stock Up 1.9%
Shares of INGN stock traded up $0.12 during trading on Monday, reaching $6.60. The company's stock had a trading volume of 140,538 shares, compared to its average volume of 241,598. The business has a fifty day moving average price of $6.65 and a 200-day moving average price of $8.29. Inogen has a one year low of $5.70 and a one year high of $13.33. The company has a market cap of $177.47 million, a price-to-earnings ratio of -5.74 and a beta of 1.64.
Inogen (NASDAQ:INGN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.27. Inogen had a negative net margin of 8.08% and a negative return on equity of 14.76%. The firm had revenue of $82.28 million for the quarter, compared to analyst estimates of $79.57 million. Research analysts anticipate that Inogen will post -1.73 EPS for the current year.
Hedge Funds Weigh In On Inogen
Several large investors have recently modified their holdings of INGN. Ieq Capital LLC bought a new position in shares of Inogen in the fourth quarter valued at about $94,000. Bank of New York Mellon Corp raised its position in shares of Inogen by 23.5% in the fourth quarter. Bank of New York Mellon Corp now owns 126,461 shares of the medical technology company's stock valued at $1,160,000 after purchasing an additional 24,082 shares during the period. AlphaQuest LLC bought a new position in shares of Inogen in the fourth quarter valued at about $43,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Inogen by 42.5% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 248,822 shares of the medical technology company's stock valued at $2,282,000 after purchasing an additional 74,197 shares during the period. Finally, Monaco Asset Management SAM raised its position in shares of Inogen by 104.0% in the fourth quarter. Monaco Asset Management SAM now owns 76,500 shares of the medical technology company's stock valued at $702,000 after purchasing an additional 39,000 shares during the period. 89.94% of the stock is owned by institutional investors.
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.